Van der Leeden H, Dijkmans B A, Hermans J, Cats A
Clin Rheumatol. 1986 Jan;5(1):56-61. doi: 10.1007/BF02030968.
To assess the benefit of further gold treatment of rheumatoid arthritis (RA) patients who had already received more than 6 g of this metal, 24 such patients were included in a double-blind trial. Besides this "gold group" comprising 11 patients who received gold (Auromyose) in the same dosage schedule as before the study, the trial included a "placebo group" comprising 13 patients who received gold in a suspension diluted 1/100. In either group clinical, laboratory, and radiological data did not differ after 6 and 24 months in relation to the results at entry except for the serum gold concentrations, which were lower in the placebo group. We conclude that discontinuation of the treatment in RA patients who have received more than 6 g gold is not harmful to the patients for at least two years after withdrawal.
为评估已接受超过6克该金属治疗的类风湿关节炎（RA）患者进一步接受金制剂治疗的益处，24例此类患者被纳入一项双盲试验。除了由11例患者组成的“金制剂组”，这些患者按照与研究前相同的剂量方案接受金制剂（金诺芬）治疗外，该试验还包括一个由13例患者组成的“安慰剂组”，他们接受的是稀释1/100的金制剂混悬液。除了安慰剂组血清金浓度较低外，在6个月和24个月时，两组的临床、实验室和放射学数据与入组时的结果相比均无差异。我们得出结论，对于已接受超过6克金制剂治疗的RA患者，停药至少在停药后两年内对患者无害。
